Biofarm recorded a turnover of 208.9 million RON, up 17%, and a net profit of 65.7 million RON, up 20%, compared to the same period of last year, according to a press release sent to AGERPRES on Wednesday.
At the same time, Biofarm recorded EBITDA of 89.4 million RON, by 18% more compared to the first nine months of the previous year.
"The very good results recorded in the last nine months validate our strategy to offer customers innovative products that contribute to their well-being. At the beginning of this year, we set out to introduce new products to the market that become leaders in their category and we achieved this with Biofen Extra, which dominates the pain management category, in the ibuprofen and paracetamol segment. Biofarm will continue to develop its portfolio through line extensions or new product launches and we aim to expand into new markets," said Catalin Vicol, general director of Biofarm.
In the first nine months of 2022, Biofarm ranked 3rd in the Consumer Healthcare (CHC) segment, in terms of the number of units sold.
The Biofarm portfolio covers the most important therapeutic areas in the Consumer Healthcare division - digestive & metabolic, respiratory & Ear-Nose-Throat (ENT), cardiovascular & circulatory, nervous system, multivitamins, with over 20 representative brands.
Biofarm is one of the first Romanian producers of medicines and food supplements. Biofarm has a competitive portfolio of products covering 65 therapeutic areas and continuously invests in media, commercial and marketing campaigns to promote its own products.
Comentează